Cepeprubart

西派扑拜单抗

Report date: 2023/12/28 17:35:17

Base Information

Drug NameCepeprubart
Drug Alias NameAnti P-selectin glycoprotein ligand-1Anti-PSGL-1-mAbSelK-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionP-selectin glycoprotein ligand-1 inhibitors
TargetsP-selectin glycoprotein ligand-1
Therapy Area/IndicationsVenous ThromboembolismPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUkrainePoland +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSelexys
China Registration ClassN/A

Develop Information

Active CompaniesTetherex Pharmaceuticals Co
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsVenous Thromboembolism

Other Information

ATC CodeN/A
Related LinksN/A